mounjaro glp-1 market impact Receptor Agonist Size, Share & Forecast, 2026–2034 Mounjaro GLP1 leader in 2024
Description
It may prompt closer attention to how Novo Nordisk balances price, volume and portfolio mix, and how peers respond as similar patent cliffs approach globally
GLP-1 analogs have a similar structure to endogenous GLP-1, mimicking its actions in the pancreas, stomach, and brain
i.e., a 10-15% lower risk of fractures with GLP-1 RAs
Participants were randomly assigned to one of five therapies: exenatide alone, dapagliflozin alone, dual therapy of exenatide and dapagliflozin, combined dapagliflozin and metformin therapy, or the weight-loss medication phentermine/topiramate extended-release
Do my health conditions require in-person monitoring rather than telehealth-only care
Duration : The program runs from July 1, 2026 through December 31, 2027, after which the BALANCE Model is scheduled to begin
